Davis's Drug Guide
donanemab
General
Genetic Implications:
Pronunciation:
doe-nan-e-mab
Trade Name(s)
- Kisunla
Ther. Class.
anti-Alzheimers's agents
Pharm. Class.
monoclonal antibodies
anti amyloid monoclonal antibodies
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Donanemab." Davis's Drug Guide, 19th ed., F.A. Davis Company, 2025. Medicine Central, im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/3580043/all/donanemab.
Vallerand AHA, Sanoski CAC, . Donanemab. Davis's Drug Guide. F.A. Davis Company; 2025. https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/3580043/all/donanemab. Accessed April 17, 2025.
Vallerand, A. H., Sanoski, C. A., & , (2025). Donanemab. In Davis's Drug Guide (19th ed.). F.A. Davis Company. https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/3580043/all/donanemab
Vallerand AHA, Sanoski CAC, . Donanemab [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2025. [cited 2025 April 17]. Available from: https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/3580043/all/donanemab.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - donanemab
ID - 3580043
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - ,,
BT - Davis's Drug Guide
UR - https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/3580043/all/donanemab
PB - F.A. Davis Company
ET - 19
DB - Medicine Central
DP - Unbound Medicine
ER -
